RecruitingPhase 4

Nasal Antisepsis for C. Auris Prevention

United States120 participantsStarted 2024-01-29

Plain-language summary

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking

What they're measuring

Detection of C. auris from the anterior nares

Timeframe: Through study completion and data analysis in three years (2028)

Trial details

NCT IDNCT06282510

SponsorMary K Hayden

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Sarah E. Sansom, DO

3125636201 sarah_e_sansom@rush.edu

View on ClinicalTrials.gov More Candida Auris Infection trials